Correlation Between Serum Level of Carboxyl-Terminal Collagen Type 2 (CTX-II) and Severity of Knee Osteoarthritis
[1]
Batool Zamani, Kashan University of Medical Science, Faculty of Medicine, Department of Internal Medicine, Rheumatology lab, Beheshti Hospital, Kashan, Iran.
[2]
Maryam Saidi, Kashan University of Medical Science, Faculty of Medicine, Department of Internal Medicine, Rheumatology lab, Beheshti Hospital, Kashan, Iran.
[3]
Fatemeh Atoof, Tehran University of Medical Science, Faculty of Health, Department of Epidemiology and Statistics, Tehran, Iran.
[4]
Hamidreza Masror, McGill University, Faculty of Medicine, Department of Experimental Surgery, Jewish General Hospital, Montreal, Quebec, Canada.
Objective: Osteoarthritis is the most prevalent joint disease. Its diagnosis is based on clinical signs and radiological findings. Carboxyl-Terminal Collagen Type 2 (CTX-II) is a measurable product of the cartilage destruction that occurs during this disease. This study was done to evaluate the correlation between this biomarker and the severity of a patient’s osteoarthritis. Material and Methods: This cross-sectional study was done on 110 patients above the age of 45 years, diagnosed with knee osteoarthritis according to American College of Rheumatology (ACR) criteria. After obtaining informed consent from the patients and recording their demographic data, 5 ml blood samples were sent to the laboratory to measure the level of CTX-II. To measure the severity of their osteoarthritis, radiographies were taken of the patients’ knees in a standing position. The disease was then classified into four different grades after radiography. Results: 32.7% of patients were in grades I, II (mild), 35.5% were in grade III (moderate) and 31.8% were in grade IV (severe). CTX-II mean levels were 373±52.8 ng/ml in mild, 476±67.1 ng/ml in moderate and 586.2±87.7 ng/ml in the severe radiologic group with a significant correlation (p-value <0.001). The mean levels had significant correlation with pain during activity and at rest, pain severity according to the Visual Analogue Scale (VAS), morning stiffness, crepitation, radiologic grading, and swelling of the knee. Conclusion: This study showed a strong association between clinical/radiological signs of osteoarthritis and CTX-II levels in patients who had knee osteoarthritis; therefore this biomarker can be used to determine the severity of knee osteoarthritis and allows for early diagnosis.
Knee Osteoarthritis, Radiologic Severity, Carboxyl-Terminal Collagen Type 2
[1]
Felson DT. Ostepoarthritis. In: Longo DL. Fauci AS. Kasper DL. Hauser SL. Larry Jamson JL. Harrison's principle of internal medicine. 18thedition. Mc Graw Hill: 2012.pp.2828-2836.
[2]
Hochberg MC. Clinical Features and treatment. In: Klipple JH. Primer on the rheumatic disease. Atlanta, Arthritis foundation, 1997: 218-221.
[3]
Dennison E. Cooper C. Osteoarthritis: Epidemiology and classification.IN: Hochberg MC, Silman AJ. Smolen JS. Weinblatt ME. Weisman MH. Rheumatology. Edinburg, Mosbey 2003:1781-1791.
[4]
Ofluoglu D. Ofluoglu O. Assesment of disease activity and progression of Osteoarthritis with using molecular markers of cartilage and synovium turnover.Current Rheumatology Reviews 2005, 1:29-32-5.
[5]
Kellgren JH. Lawrence JS. Radiological Assesment of Osteoarthrosis. Ann Rheum Dis 1957, 16:494-502.
[6]
Henrotin Y, Addison S, Kraus V, Deberg M. Type II collagen markers in osteoarthritis: What do they indicate? Curr Opin Rheumato.2007; 19:444-450.
[7]
Ishikawa T, Nishgaki F, Christigau S. cartilage destraction in collagen induced arthritis assessed with a new biochemical marker for collagen type II C-telopeptide fragments. J Rheumatol2004; 31:1174-1179.
[8]
DeGrootj RA. Tchetverikov I. Verziji N. Tekoppele JM. Molecular markers for osteoarthihis: the road ahead.curr opin Rheomatol 2002:14:585-589
[9]
Tanishi N. Yamagiwa H. Relationship between radiological knee osteoarthritis and biochemical markers of cartilage and bone degradation. J Bone Metab; 2009, 27:605-612.
[10]
Garnero p. piperno M.Gineyts E.christgau s.Delmas pd.vignon E. Cross sectional evaluation of biochemical markers of bone, cartilage and synovial tissue metabolism in patients with knee osteoarthritis: relation with disease activity and joint damage Ann Rheum Dis .2001; 60:619-626
[11]
Bay-jensen AC.Liu Q.Byrjalsen I. Enzyme-Linked immunosorbent assay for metalloproteinase derived type II collagen neoepitope. CIIM-Increased serum CIIM in subject with severe radiographic osteoarthritis.clin Biochem 2011:44:423-429.
[12]
Garnero p. landewe R. Boers M. Verhoeven A. Van Der linden S. Christgau S.Van Der Heijde D.Boonen A.Geusens p (2002) Association of baseline levels of markers of bone and cartilage degradation with long-tern progression of joint damage in patients with early rheumatoid arthritis.The COBRA study.Arthritis Rheum 46:2847-2856.
[13]
Carlos J. Lozada, Roy D. Altman. Management of osteoarthritis, In: William J. koopman, Larry W. Moreland, Editors. Arthritis and Allied Conditions. 15th ed. Philadelphia: Lippincott William & wilkins.2005 p 2257 – 2271
[14]
Dougados M. Clinical feature of osteoarthritis .In: Edward D. Harris, JR, Rolph C. Budd, Gary S. Fibrestein, Mark C. Genovese, Johns. Serjent, Shaun Ruddy, Clement B. Sledge. Editors Kelleys text book of Rheumatology 19th ed. Philadelphia. Pennsylvania; 2013: 1520-1532.
[15]
Matyas JR, Atley L, Lonescu M. Analysis of cartilage biomarkers in the early phases of canine experimental osteoarthritis .Arthritis Rheum 2004;50:543-552.
[16]
Meulenbelt I, Kloppenburg M, Kroon HM, Houwing-Duistermaat JJ, Garnero P, Hellio Le Graverand MP, Degroot J, Slagboom PE. Urinary CTX-II levels are associated with radiographic subtypes of osteoarthritis in hip, knee, hand, and facet joints in subject with familial osteoarthritis at multiple sites: the GARP study. Ann Rheum Dis. 2006; 65(3):360-5.
[17]
Jordan KM, Syddall HE, Garnero P. Urinary CTX-II and Glucosyl galactosyl-pyridinoline are associated with the presence and severity of radiographic knee osteoarthritis in men.Ann Rheuma Dis.2006;65:871-877.
[18]
Reijman M., Hazes J. M. W., Bierma-Zeinstra S. M. A., Koes B. W., Christgau S., Christiansen C., Uitterlinden A. G., and H. A. P. Pols. A New Marker for Osteoarthritis. ARTHRITIS & RHEUMATISM 2004; 50(8): 2471–2478.
[19]
Duclos ME, Roualdes O, Cararo R, Rousseau JC, Roger T, Hartmann DJ. Significance of the serum CTX-II level in an osteoarthritis animal model: a 5-month longitudinal study. Osteoarthritis Cartilage. 2010; 18(11):1467-76.
[20]
Wang XZ, Gao NY, Liu T, Shen J, Wei SP, Zheng YX, Cao YL, Zhan HS. Application of biomarker CTX- II in osteoarthritis. Zhongguo Gu Shang. 2013 Mar; 26(3):260-3.
[21]
Garnero P, Sornay Rendu E, Arlot ME, et al. Association between spine disc degeneration and type II collagen degradation in postmenopausal women: The OFELY Study. Arthritis Rheum 2004; 50:3137-44.
[22]
Gareno P. Biochemical markers in osteoarthritis: will they meature up? Nat Clin Pract.2006; 2:116-117.
[23]
Sharif M, Kirwan J, Charni N. A 5 years longitudinal study of type IIA collagen synthesis and total type II collagen degradation in patients with knee osteoarthritis: association with disease progression. Rheumatology.2007; 46:938-943.
[24]
Deberg M, Labasse AH, Collette. One-year increase in Coll2-1 ad new marker of type II collagen degradation in urine is highly predictive of radiographical OA progression. Ostearthritis Cartilage.2005; 13:1059-1065.
[25]
Deberg M, Dubuc JE, Labasse A. One year follow-up of Coll2-1, coll2-1NO2 and myeloperoxidase serum level in OA patients after hip or knee replacement.Ann Rheum Dis. 2007; 234-239.
[26]
SW, Haavardshow EA, Boyesen P. Biomarkers in early Rheumatoid arthritis: longitudinal association with inflammation and joint destrsaction measured by magnetic resonance imaging and convertional radiography. Ann Rheum Dis. 69(5):845-850.
